jounce.png
Jounce Therapeutics Regains Worldwide Rights to JTX-8064 from Bristol Myers Squibb
June 04, 2020 08:00 ET | Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., June 04, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
PMCB YT .png
PharmaCyte Biotech’s Pancreatic Cancer Therapy Passes Critical FDA-Required Tests as Countdown to IND Submission Begins
January 27, 2020 09:00 ET | PharmaCyte Biotech
NEW YORK, NY, Jan. 27, 2020 (GLOBE NEWSWIRE) -- PharmaCyte Biotech (OTCQB: PMCB) announced that its clinical trial product, which will be employed during the company’s upcoming Phase 2b clinical...
Hausfeld logo
Celgene Rescinds Agreement to Compensate Cancer Patients Days Before Christmas
January 08, 2020 13:36 ET | Hausfeld
WASHINGTON, Jan. 08, 2020 (GLOBE NEWSWIRE) -- On December 23, 2019, Celgene backed out of a settlement in which it had agreed to pay $55 million to end payors (consumers, insurers, union health and...
jounce.png
Jounce Therapeutics Reports Second Quarter 2019 Financial Results
August 07, 2019 06:30 ET | Jounce Therapeutics, Inc.
- Initiated Phase 2 EMERGE trial of vopratelimab - - Completed enrollment of Phase 1 trial of JTX-4014 - - Updated strategic collaboration and established new licensing agreement with...
Hausfeld logo
Hausfeld Announces $55 Million Settlement in Antitrust Class Action Against Celgene
July 24, 2019 11:19 ET | Hausfeld
WASHINGTON, July 24, 2019 (GLOBE NEWSWIRE) -- Hausfeld, a global claimants’ law firm dedicated to handling complex litigation, announced today that it has reached a $55 million settlement with...
jounce.png
Jounce Therapeutics Announces Update on Strategic Collaboration with Celgene Corporation
July 23, 2019 16:00 ET | Jounce Therapeutics, Inc.
- Celgene licenses JTX-8064, resulting in $50.0 million upfront payment to Jounce - - Jounce retains full worldwide rights to vopratelimab, JTX‑4014 and all discovery programs - - Company to host...
VBI-Vaccines-Vertical-Logo.png
VBI Vaccines Appoints Dr. Vlad Popovic as Vice President of Clinical Development and Medical Affairs
April 17, 2019 08:00 ET | VBI Vaccines, Inc.
CAMBRIDGE, Mass., April 17, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
PMCB YT .png
PharmaCyte Biotech Nearing Major Milestone—An Open IND with the FDA
February 04, 2019 09:20 ET | PharmaCyte Biotech
NEW YORK, NY, Feb. 04, 2019 (GLOBE NEWSWIRE) -- Clinical stage biotechnology company PharmaCyte Biotech (OTCQB: PMCB) is now closer than ever to reaching what would be a monumental milestone in the...
MaRS Innovation’s Triphase Accelerator Announces New Partnership with Celgene for First-in-class WDR5 Leukemia Therapy
January 29, 2019 08:00 ET | MaRS Innovation
Toronto, ON, Jan. 29, 2019 (GLOBE NEWSWIRE) -- Triphase Accelerator, a Toronto-based drug development company, has entered into a new strategic partnership with Celgene Corporation. The focus of the...
PMCB YT .png
World-Renowned Oncologist Bullish on Potential of PharmaCyte’s Technology, Clinical Trial in Pancreatic Cancer
January 23, 2019 09:25 ET | PharmaCyte Biotech
NEW YORK, NY, Jan. 23, 2019 (GLOBE NEWSWIRE) -- With PharmaCyte Biotech, Inc.’s (OTCQB: PMCB) naming of Medpace, Inc., a global full-service clinical contract research organization (CRO) to conduct...